Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

First clinical results from a phase 1 trial of PRT3789, a first-in-class SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation

Friday, September 13, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the first clinical results from a Phase 1 trial of PRT3789, a novel SMARCA2 degrader, in patients with advanced solid tumors harboring a SMARCA4 mutation. The trial aims to evaluate the safety and efficacy of this innovative treatment approach. Early results suggest potential benefits for patients with this specific mutation.
Price reaction · baseline $4.83 (2024-09-12 close) · hit pre-market · clean, no other PRLD news in the window
day 0 close
-42.7%
day 1
-46.2%
day 3 · peak
-49.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • First-in-class SMARCA2 degrader shows promise in clinical trials.
  • Targeting SMARCA4 mutation may offer new treatment options.
  • Involvement of multiple experts indicates strong research support.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Robin Guo, Afshin Dowlati, Ibiayi Dagogo-Jack, Julien Vibert, Alexander I Spira, Victor Moreno Garcia, Salman R Punekar, Emiliano Calvo, Guru P Sonpavde, Mark Awad, Jonathan W Riess, Tatiana Hernández-Guerrero, Benjamin Herzberg, Antoine Italiano, Aurelie Swalduz, Patricia LoRusso, Egbert F Smit, Edward B Garon, William Novotny, Timothy A Yap

Frequently Asked Questions

What is PRT3789?

PRT3789 is a first-in-class SMARCA2 degrader designed to target tumors with SMARCA4 mutations.

What type of trial is being conducted for PRT3789?

A Phase 1 clinical trial is currently evaluating the safety and efficacy of PRT3789.

Who are the researchers involved in the trial?

The trial involves multiple experts including Robin Guo and Afshin Dowlati.

What is the significance of SMARCA4 mutations?

SMARCA4 mutations are associated with certain advanced solid tumors, making them a target for therapies like PRT3789.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 solid tumors Phase 1 trial
Last updated: Sep 13, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →